Myocardial Disease and Ventricular Arrhythmia in Marfan Syndrome – a prospective study
Background: Aortic root dilatation and -dissection and mitral valve prolapse are established cardiovascular manifestations in Marfan syndrome (MFS). Heart failure and arrhythmic sudden cardiac death have emerged as additional causes of morbidity and mortality.
Methods: To characterize myocardial dysfunction and arrhythmia in MFS we conducted a prospective longitudinal case-control study including 86 patients with MFS (55.8% women, mean age 36.3yr - range 13-70yr-) and 40 age- and sex-matched healthy controls. Cardiac ultrasound, resting and ambulatory ECG (AECG) and NT-proBNP measurements were performed in all subjects at baseline. Additionally, patients with MFS underwent 2 extra evaluations during 30±7months follow-up. To study primary versus secondary myocardial involvement, patients with MFS were divided in 2 groups: without previous surgery and normal/mild valvular function (MFS-1; N=55) and with previous surgery or valvular dysfunction (MFS-2; N=31).
Results: Compared to controls, patients in MFS-1 showed mild myocardial disease reflected in a larger left ventricular end-diastolic diameter (LVEDD), lower TAPSE and higher amount of (supra) ventricular extrasystoles ((S)VES). Patients in MFS-2 were more severely affected. Seven patients (five in MFS-2) presented decreased LV ejection fraction. Twenty patients (twelve in MFS-2) had non-sustained ventricular tachycardia (NSVT) in at least one AECG. Larger LVEDD and higher amount of VES were independently associated with NSVT.
Conclusion: Our study shows mild but significant myocardial involvement in patients with MFS. Patients with previous surgery or valvular dysfunction are more severely affected. Evaluation of myocardial function with echocardiography and AECG should be considered in all patients with MFS, especially in those with valvular disease and a history of cardiac surgery.
Figure 1
Figure 2
This is a list of supplementary files associated with this preprint. Click to download.
Posted 23 Sep, 2020
On 23 Oct, 2020
On 12 Oct, 2020
Received 05 Oct, 2020
On 26 Sep, 2020
Received 26 Sep, 2020
On 24 Sep, 2020
Received 24 Sep, 2020
On 23 Sep, 2020
Invitations sent on 23 Sep, 2020
On 23 Sep, 2020
On 22 Sep, 2020
On 22 Sep, 2020
On 27 Jul, 2020
Received 26 Jul, 2020
Received 22 Jul, 2020
Received 18 Jul, 2020
On 07 Jul, 2020
On 06 Jul, 2020
On 04 Jul, 2020
On 26 Jun, 2020
Invitations sent on 26 Jun, 2020
On 25 Jun, 2020
On 25 Jun, 2020
On 25 Jun, 2020
Myocardial Disease and Ventricular Arrhythmia in Marfan Syndrome – a prospective study
Posted 23 Sep, 2020
On 23 Oct, 2020
On 12 Oct, 2020
Received 05 Oct, 2020
On 26 Sep, 2020
Received 26 Sep, 2020
On 24 Sep, 2020
Received 24 Sep, 2020
On 23 Sep, 2020
Invitations sent on 23 Sep, 2020
On 23 Sep, 2020
On 22 Sep, 2020
On 22 Sep, 2020
On 27 Jul, 2020
Received 26 Jul, 2020
Received 22 Jul, 2020
Received 18 Jul, 2020
On 07 Jul, 2020
On 06 Jul, 2020
On 04 Jul, 2020
On 26 Jun, 2020
Invitations sent on 26 Jun, 2020
On 25 Jun, 2020
On 25 Jun, 2020
On 25 Jun, 2020
Background: Aortic root dilatation and -dissection and mitral valve prolapse are established cardiovascular manifestations in Marfan syndrome (MFS). Heart failure and arrhythmic sudden cardiac death have emerged as additional causes of morbidity and mortality.
Methods: To characterize myocardial dysfunction and arrhythmia in MFS we conducted a prospective longitudinal case-control study including 86 patients with MFS (55.8% women, mean age 36.3yr - range 13-70yr-) and 40 age- and sex-matched healthy controls. Cardiac ultrasound, resting and ambulatory ECG (AECG) and NT-proBNP measurements were performed in all subjects at baseline. Additionally, patients with MFS underwent 2 extra evaluations during 30±7months follow-up. To study primary versus secondary myocardial involvement, patients with MFS were divided in 2 groups: without previous surgery and normal/mild valvular function (MFS-1; N=55) and with previous surgery or valvular dysfunction (MFS-2; N=31).
Results: Compared to controls, patients in MFS-1 showed mild myocardial disease reflected in a larger left ventricular end-diastolic diameter (LVEDD), lower TAPSE and higher amount of (supra) ventricular extrasystoles ((S)VES). Patients in MFS-2 were more severely affected. Seven patients (five in MFS-2) presented decreased LV ejection fraction. Twenty patients (twelve in MFS-2) had non-sustained ventricular tachycardia (NSVT) in at least one AECG. Larger LVEDD and higher amount of VES were independently associated with NSVT.
Conclusion: Our study shows mild but significant myocardial involvement in patients with MFS. Patients with previous surgery or valvular dysfunction are more severely affected. Evaluation of myocardial function with echocardiography and AECG should be considered in all patients with MFS, especially in those with valvular disease and a history of cardiac surgery.
Figure 1
Figure 2